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Guinea pig fat cell membranes (FCM) have been widely used in preference to thyroid membranes as a source 
of TSH receptors to investigate TSH receptor antibodies in Graves’ disease, because FCM are ostensibly 
free of other thyroid antigens. However, by FCM immunoblotting we have found: (i) 8 of 10 normal sera 
bound to determinants at 38 and 190 kDa; (ii) 17 other determinants were recognised by 60% of Graves’ 
or Hashimoto sera and by 20% of normal sera; (iii) three determinants at 65-90 kDa were recognised by 
5 of 13 Graves’ but by none of the normal or Hashimoto sera; and (iv) none of the determinants recognised 
appeared to be related to the TSH receptor. 
Thyrotropin receptor antibody; Graves’ disease; Autoantibody 
1. INTRODUCTION 
Graves’ disease is almost certainly caused by an- 
tibodies directed against the thyrotropin (TSH) 
receptor [ 11. The most frequently used assay for 
TSH receptor binding immunoglobulins (TBI), 
which may or may not have thyroid-stimulating 
properties, measures inhibition of TSH binding to 
thyroid membranes [2]. Because Graves’ sera also 
contain antibodies which react with other thyroid 
components, such as thyroglobulin and micro- 
somes, recently developed assays have used guinea 
pig fat cell membranes (FCM), which contain TSH 
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receptors, but not Tg or M, to detect TBI [3-51. 
FCM binding has also been used to investigate TBI 
interactions with the receptor and to purify these 
IgG [6-81. However, the possibility that FCM con- 
tains other antigens recognised by Graves’ sera 
(besides the TSH receptor), has not been in- 
vestigated. We have therefore performed im- 
munoblotting studies to address this point. 
2. MATERIALS AND METHODS 
2.1. Materials 
FCM were prepared exactly as described in [4] 
from guinea pig subcutaneous and epididymal fat. 
This preparation was shown to be active in an 
FCM ELISA prior to use [4]. Protein concentra- 
tion was estimated by the Coomassie blue dye 
binding microassay [9]. Bovine TSH was from 
Armour (Kankakee, IL), human chorionic 
gonadotropin (HCG) from Ayerst (New York) and 
‘*‘I-TSH from Clinetics (Tustin, CA). 
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2.2. Methods 
SDS-polyacrylamide gel electrophoresis (5- 15 070 
gradient) was performed as in [lo]. FCM were run 
at 800 /cg/gel (gels 15 ml volume, 1.5 mm 
thickness) with 5% fl-mercaptoethanol. Im- 
munoblotting was performed according to [ 111. 
Sera from controls, or patients with Graves’ or 
Hashimoto’s disease, were used at 1: 50 dilution in 
50 mM Tris, 150 mM NaCl buffer (pH 7.4) with 
3% Tween and 0.5% Triton X-100. Bound IgG 
was detected with 1251-protein A and autoradio- 
graphy. Molecular masses were assigned using an 
NA2 sequence analyzer [ 121. The FCM ELISA was 
as described [4], results being expressed as U/ml 
from a standard curve generated with a strongly 
positive serum. 
3. RESULTS 
Over 40 separate protein bands were identified 
FCM 
Fig. 1. SDS-polyacrylamide gel electrophoresis of guinea 
pig FCM after Coomassie blue staining. Numbers on the 
left indicate molecular masses (in kDa). 
on Coomassie blue staining of FCM after 
polyacrylamide gel electrophoresis (fig. 1). Repre- 
sentative immunoblots are shown in fig.2 and the 
frequency distribution of the determinants re- 
cognised by these sera is shown in fig.3. Two bands 
of 190 and 38 kDa were recognised by 8 of 10 nor- 
mal sera, and by all the Graves’ and Hashimoto 
sera. One normal serum also reacted with an addi- 
tional 9 bands in the range 27-l 15 kDa, and a se- 
cond normal serum reacted with 4 bands between 
30 and 40 kDa. Sera from the Graves’ patients 
reacted with 17 discrete determinants between 15 
and 115 kDa but any single determinant was never 
recognised by more than 8 of the 13 sera. Five 
Graves’ sera showed no other reactivity than at 190 
and 38 kDa. The Hashimoto sera gave a reactivity 
pattern between that of the Graves’ and normals. 
However, none of the Hashimoto or normal sera 
reacted with three determinants identified up to 
five of the Graves’ sera between 65 and 90 kDa @ 
< 0.05, Fisher’s exact test). 
The sera from the two Graves’ patients which 
reacted with the greatest number of determinants 
(12 and 15) reacted most strongly in the FCM 
ELISA (980 and 738 U/ml). Moreover the two 
normal sera which reacted by immunoblotting 
were also reactive in the ELISA (206 and 
190 U/ml; mean f SD of other 8 normal sera 
28 f 23 U/ml). The Graves’ sera which did not 
react with immunoblots had ELISA values from 67 
to 224 U/ml. 
To assess the effect of reducing conditions on 
antigen reactivity, the FCM was run on a single gel 
with or without ,&mercaptoethanol; the binding of 
a normal and four Graves’ sera was the same in 
each case. In another experiment TSH (10 or 
100 mu/ml) and HCG (5, 50 or 500 USP U/ml) 
were shown to have no effect on the immunoblots 
of the two most reactive Graves’ sera. With TSH 
(1 U/ml), there was a reduction in intensity of a 
single band (32 or 28 kDa) with each serum (shown 
for one serum in fig.4). TSH at any concentration 
had no effect on the intensity or number of bands 
produced by a pool of five other Graves’ sera or on 
the two bands identified by a pool of five control 
sera. Furthermore, we found no binding of 12?- 
TSH (added at up to 5 x lo5 cpm) to blotted FCM 
on the nitrocellulose strips. 
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Fig.2. Immunoblots of normal and autoimmune sera against FCM. N, normal; H, Hashimoto’s thyroiditis; G, Graves’ 
disease; P, pool of sera; numbers refer to representative individuals (nos l-3). Molecular masses (in kDa) are indicated 
on the left. 
Fig.3. The frequency distribution of various FCM 
determinants recognised by the three groups of sera. 
Each line shows the number of sera which reacted with 
a given determinant identified by its molecular mass (in 
kDa, indicated to the left). 
Fig.4. Effect of TSH and HCG on the binding of a 
Graves’ serum to FCM by immunoblotting. Molecular 
masses (in kDa) indicated on the left. 
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4. DISCUSSION 
These results show the presence of previously 
unsuspected antibody heterogeneity in the reaction 
of Graves’ and Hashimoto sera with guinea pig 
FCM. It is unlikely that the determinants identified 
by immunoblotting were related to the TSH recep- 
tor. The molecular masses of the bands which 
discriminated Graves’ from Hashimoto sera 
(65-90 kDa) do not correspond with the known 
size of the guinea pig FCM TSH receptor subunits 
[ 131, and antibody binding to the immunoblots 
could not be inhibited by TSH at up to 
100 mu/ml. It is difficult to know whether the 
reduction in binding to bands at 28-32 kDa with 
two sera at 1 U TSH/ml is truly specific inhibition 
[14]. Even if this were to represent a TBI binding 
to the 30 kDa TSH receptor B subunit [13], it is 
clear that the other determinants found by im- 
munoblotting cannot be related to this. 
We also found reactivity of some normal and 
Hashimoto sera with FCM antigens by im- 
munoblotting. These data are consistent with other 
reports showing normal and Hashimoto sera 
binding to FCM in solid-phase immunoassays 
[ 15,161. Normal sera have been shown to im- 
munoprecipitate non-specifically FCM proteins 
[ 141. It is possible that some of the reactivity found 
with normal sera is associated with heterophile an- 
tibody activity against guinea pig species-related 
antigens [16]. 
In conclusion it is apparent hat under these im- 
munoblotting conditions TBI cannot be demon- 
strated with FCM, yet sera from Graves’, 
Hashimoto, and to a lesser extent normal subjects 
contain antibodies directed against several other 
determinants in FCM. This reactivity could explain 
the lack of correlation with TBI in some FCM- 
based antibody assays [15,16] and questions the 
use of such material as a source of TSH receptors 
implicitly free from other contaminating antigens. 
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